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Glucocorticoids (gcs) are known to be effective in the treatment of asthma. In chronic obstructive pulmonary disease 
(COPD), however, no beneficial effects are demonstrated in most patients. Hypothetically, this may be explained by 
an overexpressed p-glucocorticoid receptor (GR) compared to the a-GR. The aim of this study was to investigate 
a- and P-GR mRNA levels and ratios in patients with COPD with or without glucocorticoid treatment. 
GR and, as a control, metallothionein (MT) 2 mRNA levels were compared between patients with COPD 
receiving glucocorticoids (COPD + gcs), glucocorticoid naive COPD-patients (COPD - gcs) and non-COPD control 
patients not using gcs. Bronchoscopy was performed and bronchial epithelial cells were sampled with brushing. 
Smoking did not influence a- and ,Li’-GR levels and ratios, nor the MT2 mRNA expression level. The a-GR mRNA 
expression was lower in the COPD - gcs group than in controls. Both GR forms were higher in the COPD+gcs 
patients than in the COPD - gcs patients, but not different from the levels measured in the controls. al//~‘-GR 
mRNA ratios did not differ between the groups and averaged 1.7, suggesting no inhibitory effect of the P-GR on the 
al form. MT2 levels were upregulated in the COPD + gcs patients as compared to the COPD - gcs group, indicating 
a pharmacological glucocorticoid effect. 
In the present study it is demonstrated that basal GR mRNA levels are lower in patients with COPD. Although 
this needs to be investigated further, this might explain, in part, the non-responsiveness of patients with COPD 
to gcs. 
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Introduction 
Glucocorticoids (gcs) have proven to be effective in the 
long-term management of asthma. Symptoms and airway 
hyperresponsiveness are reduced, lung function improved 
and airway integrity restored (1). Only a small proportion 
of asthma patients do not respond to gcs. In contrast, 
effects of gcs in patients with chronic obstructive pul- 
monary disease (COPD) are limited (2,3). Callahan et al. 
demonstrated in only 10% of the patients a response to oral 
corticosteroid therapy, measured as a 20% increase in 
baseline FEV, (4). The beneficial effects of glucocorticoids 
in COPD are at present still under study (5), and the results 
of this investigation will be available soon. The reason for 
the limited response to glucocorticoids in patients with 
COPD is not yet elucidated. 
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The molecular mechanisms involved in the anti- 
inflammatory actions of glucocorticoids are not completely 
understood. Glucocorticoids enter the cell by passive diffu- 
sion and bind to a cytoplasmic glucocorticoid receptor 
(GR). This receptor mediates the effect of glucocorticoids by 
translocating into the nucleus, binding to glucocorticoid 
responsive elements (GRE) in the DNA and modulating the 
transcription of genes (6). Another way of regulating the 
transcription of genes does not involve binding of the GR to 
DNA but the interaction of CR with other transcription 
factors. Cross-talk between the GR and proinflammatory 
transcription factors, like activator protein-l (AP-1) (7,8) 
and nuclear factor KB (NFKB) (9,10), has been demonstrated 
within the cell. This interaction is believed to be important 
for the anti-inflammatory effect of glucocorticoids (11). 
Direct protein-protein interaction of the GR has not only 
been described with AP-1 and NFrcB, but also with CAMP- 
responsive element binding protein (CREB) (12,13) and 
signal transducers and activators of transcription 5 (Stats) 
(14). In asthma, steroid resistance might be due to a reduced 
binding of the activated glucocorticoid receptor to DNA, 
caused by high AP-1 concentrations (15). No information is 
available about the GR expression and interactions with 
other transcription factors in patients with COPD. 
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As a result of alternative splicing, the glucocorticoid 
receptor exists in two forms, a and p (16). Both a and P-CR 
mRNAs are present in all tissues investigated (17,18); but 
because of its ligand binding capacity, the o. form has been 
the primary target in research (16;18). The levels of GR 
expression vary between cell types and individuals, but in 
all cases higher a-GR mRNA expression levels have been 
observed compared to P-GR mRNAs (18). Recently, 
Oakley et al. (18), reported the existence of 2 a-GR iso- 
forms: al and a2 with Northern blot analysis. The al, ~2, 
and /3 bands were demonstrated at 7 kb, 5.5 kb; and 4.3 kb, 
respectively. However, translation of both D forms results in 
the same GR protein. The fact that the /3 form is widely 
expressed in many cell types, indicates that it may play a 
role in the cellular response to glucocorticoids. It has been 
demonstrated that the P-GR acts as a dominant negative 
inhibitor on the transcriptional activity of the a-GR at an 
a/p ratio well below 1 (17). Thus, a predominant expression 
of the P-GR mRNA over the a-GR mRNA could explain a 
lack of response to steroids as observed in steroid resistant 
asthma and COPD. Therefore, it is important to study both 
GR forms in COPD. 
The aim of the present study was (1) to investigate a and 
/?-GR levels and ratios in bronchial epithelial cells of 
patients with COPD and (2) to assess the effect of gluco- 
corticoids in these patients. Since the amount of cells 
obtained from human bronchial epithelial cells ifz vivo is 
limited and no antibodies are available to separately inves- 
tigate both GR forms, we chose to study the a and P-GR 
at mRNA level. As a control gene, metallothionein 
mRNA levels were studied, since this gene is known to be 
upregulated by glucocorticoids. 
Methods 
PATIENTS 
In this cross-sectional study, three patient groups were 
investigated. COPD patients receiving glucocorticoids 
(IZ= 12); patients with COPD using no glucocorticoids 
(n=6), and. controls, i.e. patients without pulmonary 
obstruction (n= 14). COPD was defined according the 
standards of the American Thoracic Society (19). Pulmon- 
ary function tests and bronchoscopies were performed 
according to the guidelines of the European Respiratory 
Society (20) and American Thoracic Society (21); respect- 
ively. Smoking status was recorded and non-smoking was 
defined as ‘stopped smoking for more than 5 years’. The 
control group existed of patients with lung cancer (~z= lo), 
patients with haemoptysis (n=3) and one patient with 
unexplained cough. From the patients with lung cancer, 
bronchial brushings were performed from second to fourth 
order bronchi of the non-malignant contralateral lung. 
&-agonists (at least 3 x 4OOpg albuterol daily) were used 
by all patients with COPD using glucocorticoids 
(COPD+gcs) but by only two COPD patient in the gluco- 
corticoid free group (COPD - gcs). The controls neither 
used glucocorticoids nor &agonists. Patients in the 
COPD+gcs group were under maintenance gcs therapy in 
variable doses of inhaled glucocorticoids (ICS, at least 
2 x 4OOpg of either budesonide or beclamethasone). Two 
COPD patients were hospitalized during bronchoscopy and 
received additional iv. prednisone. The interval between 
last dose of ICS and bronchoscopy was not standardized. 
Four patients underwent bronchoscopy 3 h after the last 
dose of ICS, three patients after a time interval of more 
than 10 h, three underwent bronchoscopy within 2 h of the 
last dose and of two patients the time between inhalation 
and bronchoscopy was unknown. The protocol has been 
approved by the local ethical committee. 
RNA-ISOLATION, NORTHERN BLOTTING AND 
HYBRIDIZATION 
RNA was isolated from the cells as described before by 
Korn et al. (22). In short: 10 brush samples were taken from 
the second to fourth order bronchi and cells were firmly 
shaken into 4 ml DMEM. Immediately after collection, an 
equal amount of 8 M GTC was added. Total RNA was 
isolated with the GTC/CsCl-method and 20 Llg was run on 
gel for Northern blot analysis. The glucocorticoid receptor, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
metallothionein (MT2) probes were subsequently hybrid- 
ized. Both 0: forms and the p form are detected with the 
GR-probe. The MT2 mRNA is known to be upregulated 
by glucocorticoids and served as a positive control. The 
gene has 2 GREs in its promotor sequence (DNA Stock 
Center, Japan). Sample signals were analyzed visually as 
well as semiquantitatively with a phosphorimaging system 
(Molecular Dynamics, Sunnyvale, CA, U.S.A.). GR and 
MT2 mRNA levels were expressed relative to GAPDFI 
levels of the same sample. 
CYTOLOGY 
To determine the cellular composition of the brushes, 
smears were made by spreading one additional brush on 
an object glass. Cells were Giemsa stained, and cellular 
composition analysed as described before (23,24). 
STATISTICS 
For all results mean & standard deviation (SD) was calcu- 
lated. To determine differences the Mann-Whitney U test 
or X2-square test were performed. Differences of PcO.05 
were considered to be statistically significant. 
Results 
CLINICAL CHARACTERISTICS OF THE 
PATIENTS 
Clinical characteristics and smoking status of the patients 
with COPD and the control group are shown in Table 1. 
Age, gender and smoking status did not differ between the 
three groups. As expected the FEV, was lower (PcO.05) in 
patients with COPD compared to the control group, 51% 
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TABLE 1. Clinical characteristics of the patients 
Patient 
Steroid Age Sex FEV, FEV, DLCO Smoking 
+I- year M/F Disease % pred. % rev. % pred. y/n 
1 - 64 
2 - 52 
3 - 72 
4 - 74 
5 - 74 
6 - 73 
I + 67 
8 + 13 
9 + 62 
10 + 67 
11 + 68 
12 + 62 
13 + 73 
14 + 67 
15 + 71 
16 + 57 
17 + 67 
18 + 12 
19 - 48 
20 - 58 
21 - 77 
22 - 61 
23 - 63 
24 - 36 
25 - 61 
26 - 72 
27 - 49 
28 - 61 
29 - 69 
30 - 73 
31 - 74 
32 - 52 
M 
F 
M 
M 
M 
M 
M 
F 
M 
F 
M 
M 
F 
F 
M 
M 
F 
M 
M 
M 
M 
F 
M 
F 
M 
M 
M 
M 
M 
M 
M 
M 
COPD 12 
COPD 66 
COPD 47 
COPD 71 
COPD 48 
COPD 62 
COPD 33 
COPD 41 
COPD 65 
COPD 32 
COPD 32 
COPD 45 
COPD 69 
COPD 38 
COPD 70 
COPD 51 
COPD 41 
COPD 34 
Cancer 17 
Cancer 87 
Cancer 84 
Cancer 81 
Cancer 83 
Cancer 103 
Haemoptoe nd. 
Haemoptoe 111 
Haemoptoe 136 
Cough 96 
Cancer 96 
Cancer 86 
Cancer 93 
Cancer 100 
10 
2 
3 
6 
4 
0 
0 
n.d. 
5 
0 
5 
2 
0 
2 
n.d. 
I 
5 
4 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
nd. 
124 Y 
46 Y 
47 Y 
104 Y 
74 n 
59 Y 
43 Y 
n.d. Y 
68 Y 
59 Y 
62 n 
70 Y 
74 n 
93 n 
85 Y 
n.d. Y 
51 Y 
12 n 
124 Y 
133 Y 
54 Y 
n.d. Y 
86 Y 
91 Y 
n.d. Y 
94 n 
123 n 
147 n 
108 Y 
90 n 
89 Y 
120 Y 
n.d., Not determined. 
and 95% respectively. Additionally, the FEV, in patients 
with COPD - gcs was higher (WO.05) compared to the 
COPD-t-gcs group. The percentage FEV, reversibility 
(gained to &-agonist) in the COPD+gcs patients was 
3.0 + 2.4% and from COPD - gcs patients was 4.2 f 3.2%. 
The diffusion capacity (DLCO) was lower (WO.05) in 
patients with COPD + gcs as compared to the controls: 68% 
and 105%, respectively. In the COPD - gcs group the 
DLCO (76%) tended to be lower than in the controls 
(P=O.O8). 
CELL COUNTS 
In Table 2 the cellular composition from the brush 
specimens is presented. The majority of the cell types were 
epithelial in origin (average >85%). Although the COPD 
patients on average seem to have more neutrophilic 
granulocytes, due to the large variation no significant 
difference was observed in cell differential counts obtained 
from brushes of patients with COPD and the non- 
obstructive control group. Neither was there a significant 
difference in cell types between brushes from smokers and 
non-smokers. 
TABLE 2. The relative cellular distribution of brushes given 
in percentages 
Cell types 
Control 
COPD + gcs COPD - gcs brush 
Epithelial cells 81 -f20 78518 91rt8 
Macrophages 2+2 4f7 1*1 
Neutrophils 12521 10 + 13 4*5 
Eosinophils 0.1 * 0.2 0.210.4 0.2xk 0.3 
Lymphocytes 6&4 IIt9 4f4 
Basophils 0 0.2hO.3 0 
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FIG. 1. 
Smokers Non-smokers Smokers Non-smokers 
a B 
The mean f SD of al- and P-GR mRNA 
expression in brushes of patients with COPD+gcs (0) 
and the age-matched controls (m) subdivided by smoking. 
Glucocorticoid therapy did not downregulate either al- or 
,&GR mRNA in patients with COPD. 
GENE EXPRESSION 
In five patients (two COPD+gcs, two COPD - gcs and one 
control) the GR mRNA signal was too weak for reliable 
quantitation. Because smoking is an important factor in 
COPD it is essential to check whether GR mRNA levels are 
affected by smoking. Therefore all groups were subdivided 
in current smokers and non-smokers, except for the 
COPD - gcs group which only has one smoker. This group 
is not included in the first three figures. Because the a2 band 
was not detected in these blots, only al- and fi-GR mRNA 
levels were determined. 
The means and standard deviations of the al- and P-GR 
mRNA levels in bronchial epithelial cells, subdivided by 
smokers and non-smokers from each group, are shown in 
Fig. 1. The al/p ratios in the same cells from the same 
groups are shown in Fig. 2. No difference in both al- and 
/?-GR mRNA expression levels or ratios was observed 
between smoking patients with COPD+gcs and smoking 
controls using no glucocorticoids. Similar results were 
obtained for the comparison between the non-smoking 
patients and for the comparison between smokers and 
non-smokers per patient group. 
In Fig. 3 MT2 mRNA levels are given in human 
bronchial epithelial cells of COPD+gcs and controls, sub- 
divided by smokers and non-smokers. MT2 mRNA levels 
were not influenced by smoking, not in the controls (P=O,3) 
nor in patients with COPD+gcs (P=O.6). 
Because no effect of smoking on either a- and P-GR 
mRNA levels or ratios nor on MT2 mRNA levels was 
demonstrated, we concluded that smoking was not a 
confounding factor in this study. Therefore, for further 
analysis, the data within the COPD+gcs, COPD - gcs and 
control groups were combined. 
In Fig. 4, a- and P-CR mRNA levels are shown and 
compared for all three groups. Lower GR mRNA levels 
Smokers 
I 
I 
Non-smokers 
FIG. 2. al/j?-GR mRNA ratios in brush samples of 
patients with COPD+gcs (m) and controls (m). Shown 
are mean values f SD of every group, subdivided by 
smoking. 
2 0 z Smokers Non-smokers 
FIG. 3. MT2 mRNA expression in brush samples of 
patients with COPD+gcs (G) and an age-matched control 
group (m). No upregulation of MT2 mRNA was seen in 
patients with COPD+gcs compared to the controls, nor 
in the smokers compared to the non-smokers. Shown are 
mean values & SD. 
were demonstrated in the COPD - gcs patients than in the 
controls, which was significant for the a-GR (P<O,O5). A 
clear difference in expression was observed between the 
COPD +gcs and COPD - gcs group for the al-GR form, 
1.7 + 0.8 and 0.8 5 0.2 (P=O,Ol) and for the j?-GR 1.1 + 0.8 
and 0.5 & 0.1 (P=O.O3), respectively. 
Comparing the a//$GR mRNA ratios between the three 
groups no significant difference is observed (Fig. 5). The 
average ratio was 1.7 5 0.4, clearly above 1: indicating no 
inhibitory effect of the ,&GR on the a form. 
In Fig. 6, MT2 mRNA levels are demonstrated. A higher 
expression level was seen in patients with COPD using 
glucocorticoids compared to the COPD - gcs group 
(P<O.O5). There was no difference in expression between 
the controls and COPD - gcs group, nor between the 
controls and the COPD+gcs group. 
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I 
Controls COPD - gcs COPD + gcs 
FIG. 4. Given are mean al- (0) and /3- (m) GR mRNA 
expressions in bronchial epithelial cells of patients with 
COPD - gcs, COPD+gcs and a control group. Basal GR 
mRNA levels are lower in patients with COPD - gcs 
compared to the controls. The COPD+gcs demonstrate 
an upregulated a- and P-GR mRNA expression compared 
to the COPD - gcs. *P<O.O5. 
I I 
T 
I 
- 
Controls COPD - gcs COPD + gcs 
FIG. 5. The ratios between the al- and ,&CR mRNA are 
plotted. No difference is observed between the three 
groups. 
Discussion 
The aim of this study was to investigate the GR mRNA 
expression in patients with COPD. Smoking did not appear 
to influence al- and /I-GR mRNA levels and ratios nor 
MT2 mRNA levels in the bronchial epithelial cells. The 
al- and P-CR mRNA levels were lower in COPD - gcs 
than in controls. CR mRNA levels were similar between 
COPD + gcs and the control group, and significantly higher 
than in the COPD - gcs group. On average, a 1.7 times 
higher u-l GR mRNA expression was seen compared to 
the /I-GR mRNA levels. No difference in u/&GR mRNA 
ratio was observed between the three groups, indicating no 
inhibitory function from the P-GR on the activity of the 
a-GR. MT2 levels were higher in the COPD+gcs group 
compared to the COPD - gcs, but not different from the 
levels in the controls, indicating a functional response to 
glucocorticoid. 
h 
E ” Controls COPD - gcs COPD + gcs 
FIG. 6. Mean MT2 mRNA levels are shown for the 
COPD - gcs, COPD+gcs and controls. A clear higher 
expression of MT2 mRNA is observed in the patients 
using glucocorticoids (COPD+gcs) as compared to the 
COPD - gcs. *P<O.O5. 
Interestingly, basal expressions of the GR mRNA were 
lower in patients with COPD - gcs compared to the con- 
trols. This can be interpreted in two ways. First, it might be 
a pathophysiological phenomenon, resulting in a disturbed 
GR function in bronchial epithelial cells of patients with 
COPD. Since it has been demonstrated that the response of 
cells to glucocorticoids is dependent on GR protein levels 
(25-27), lower GR mRNA levels could explain the lack of 
response of patients with COPD to glucocorticoids. How- 
ever, it is unknown if these lower mRNA amounts demon- 
strated in the COPD - gcs patients are also present at 
protein level and if the translational capacity of both 
receptor mRNA forms is equal. This needs to be investi- 
gated further. An alternative explanation for the lower a-l 
and /?-GR mRNA expression may be the number of 
patients investigated. Because glucocorticoids are com- 
monly prescribed in COPD in The Netherlands, it was 
difficult to collect glucocorticoid naive COPD patients. 
When comparing the patients with COPD - gcs to the 
COPD+gcs group, an upregulated al- and /3-GR mRNA 
expression is observed in the glucocorticoid treated group 
to similar levels as in the non-obstructive control patients. 
This ‘normalization’ of the GR mRNA expression is an 
unexpected finding, since in a previous study (22) we 
demonstrated a downregulation of the al- and P-GR 
mRNA shortly after acute glucocorticoid therapy. How- 
ever, after chronic (4 weeks daily) inhalation of 16OOpg 
budesonide, on average, no change in GR mRNA expres- 
sion was observed. Only after correcting for the time 
between inhalation and bronchoscopy, an acute down- 
regulation was observed. This downregulation occurred 
after 2 h and was reversed after 10 h. There are two 
explanations for the upregulated GR mRNA expression in 
patients with COPD after glucocorticoid use. Apparently, 
basal GR mRNA levels are decreased in patients with 
COPD. Therefore, in these patients, in the inflammatory 
process the balance of transcription factors is unfavourable 
for the GR. The mechanism behind this imbalance needs 
further investigation. Arguments for functioning GRs are 
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the upregulation of the MT2 levels as well as the ‘normali- 
zation’ of the GR mRNA after GCS use in patients with 
COPD. Alternatively, the use of,&-agonists may provide an 
explanation. The patients of the COPD+gcs group all 
received ,&agonists compared to only two of the patients 
from the COPD - gcs group. Since CREB is activated by 
&-agonists and is able to interact with the GR, this might 
play a role in the upregulated, ‘normalized’ GR mRM.4 
expression. 
In a recent study of Oakley et al. (18), the GR /J’ isoform 
was studied. Similar findings as compared to the study of 
Bamberger et al. (17) were described regarding the negative 
inhibitory function of the /!-GR on the activity of the a 
form. Striking in this article was the observation that with 
Northern blot analysis three GR mRNA forms were 
present. Instead of the previously frequently mentioned 
(16,28-30) a-GR mRNA (7 kb) and P-CR mRNA (5 kb), 
an al band of 7 kb, an a2-band of 5.5 kb and a P-band 
of 4.3 kb were demonstrated (18). In a previous study 
(22) we investigated the al-GR mRNA form, which was 
abundantly expressed in both bronchial epithelial cells and 
alveolar macrophages and the P-band, which was also 
expressed in these cell types, although to a lesser extent. We 
determined the identity of these isoforms by the location of 
the 28s and 18s ribosomal bands. Occasionally in alveolar 
macrophages expressing higher amounts of GR, a faint 
third hybridization signal could be discerned, although in 
much lower levels as compared to the other two GR mRNA 
forms. This band was located just above the 28s band: 
whereas the p form was situated on the lower side of the 28s 
band, in agreement with the study of Oakley et al. (18). We 
were not able to detect the a3-GR form in the patients 
described in this study. The recent discovery of the /j-GR as 
a negative inhibitor of the a-GR might be an important 
element in the poor response to glucocorticoids in steroid 
resistant asthma or COPD (17,18). Bamberger et al. (17) 
demonstrated in a model study an increasing inhibition of 
50-85% on a/,R ratios from 0.2 to 0.07, respectively. Impor- 
tantly the al/P-mRNA ratio in the present study was 1.7, 
more than lo-fold higher than described in the article by 
Bamberger (17), rendering a possible inhibitory effect of the 
B-GR on GR-function unlikely in COPD. 
Since the GR mRNA expression may vary among differ- 
ent cell types, it is important to determine the cellular 
composition in the brush specimens. However, in this 
study, no significant increase in neutrophils or other inflam- 
matory cell types was found in patients with COPD and 
smokers, indicating that the GR gene expression studied 
mainly concerned the bronchial epithelial cell. 
Smoking is known to induce neutrophilic inflammation 
in the airways (31) either by direct chemotactic effects of 
cigarette components, such as nicotine, or by the release 
of chemokines by alveolar macrophages (32). COPD is 
characterized by airway inflammation, represented by 
larger numbers of neutrophils in the bronchoalveolar 
lavage and induced sputum (33-35). A correlation exists 
between the amount of neutrophils present in induced 
sputum and the airway obstruction and decline in lung 
function (33,36). Inflammatory stimuli, like ILl/?, IL2, lL4, 
IFNy and LPS increase the number and decrease ligand 
binding affinity of GRs in vitro (3740). If these effects 
could be extrapolated to the in rive situation in COPD, 
higher GR mRNA levels might be expected rather than 
lower CR mRNA levels. However, we did not measure 
inflammatory mediators and therefore can not draw con- 
clusions about the inflammatory status of these patients. 
MT2 mRNA levels were also investigated, since heavy 
metals, present in cigarettes, increase the transcription of 
the MT2 gene (41). No change in MT2 gene expression was 
observed in bronchial epithelial cells of smokers compared 
to non-smokers, despite the fact that heavy metals, like 
cadmium, are present in cigarette smoke (42). 
The present study demonstrates that patients with 
COPD - gcs have lower al- and /?-GR mRNA levels 
compared to a control group not receiving any glucocorti- 
coids. Although this needs to be investigated further, this 
might be a first explanation of the non-responsiveness of 
patients with COPD to glucocorticoids. 
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